Cargando…
Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature
BACKGROUND: Immune checkpoint inhibitors avoid inhibition of T-cell responses, upregulating antitumor immune response. Moreover, a dysregulation with hyperactive immune response can be caused, some of them underdiagnosed. Hemophagocytic lymphohistiocytosis is a rare and often fatal syndrome of uncon...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531226/ https://www.ncbi.nlm.nih.gov/pubmed/36195892 http://dx.doi.org/10.1186/s13256-022-03585-3 |
_version_ | 1784801858213117952 |
---|---|
author | Rubio-Perez, Jaime Rodríguez-Perez, Ángel Ricardo Díaz-Blázquez, María Moreno-García, Victor Dómine-Gómez, Manuel |
author_facet | Rubio-Perez, Jaime Rodríguez-Perez, Ángel Ricardo Díaz-Blázquez, María Moreno-García, Victor Dómine-Gómez, Manuel |
author_sort | Rubio-Perez, Jaime |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors avoid inhibition of T-cell responses, upregulating antitumor immune response. Moreover, a dysregulation with hyperactive immune response can be caused, some of them underdiagnosed. Hemophagocytic lymphohistiocytosis is a rare and often fatal syndrome of uncontrolled and ineffective hyperinflammatory response that triggers an inflammatory cascade that can lead in many cases to death. CASE PRESENTATION: We report the case of a 67-year-old Caucasian man with stage IV lung adenocarcinoma who developed hemophagocytic lymphohistiocytosis after initiation of atezolizumab, an antagonist of programmed death-ligand 1. Even with early diagnosis and proper treatment, death occurs in approximately half of all cases reported. CONCLUSION: Key markers are needed to better identify patients at risk of developing severe immune-related adverse events. In addition to key markers, a higher degree of suspicion and early intervention are needed to improve outcomes in acquired hemophagocytic lymphohistiocytosis, especially with the increasingly and expanding use of immune activation. |
format | Online Article Text |
id | pubmed-9531226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95312262022-10-04 Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature Rubio-Perez, Jaime Rodríguez-Perez, Ángel Ricardo Díaz-Blázquez, María Moreno-García, Victor Dómine-Gómez, Manuel J Med Case Rep Case Report BACKGROUND: Immune checkpoint inhibitors avoid inhibition of T-cell responses, upregulating antitumor immune response. Moreover, a dysregulation with hyperactive immune response can be caused, some of them underdiagnosed. Hemophagocytic lymphohistiocytosis is a rare and often fatal syndrome of uncontrolled and ineffective hyperinflammatory response that triggers an inflammatory cascade that can lead in many cases to death. CASE PRESENTATION: We report the case of a 67-year-old Caucasian man with stage IV lung adenocarcinoma who developed hemophagocytic lymphohistiocytosis after initiation of atezolizumab, an antagonist of programmed death-ligand 1. Even with early diagnosis and proper treatment, death occurs in approximately half of all cases reported. CONCLUSION: Key markers are needed to better identify patients at risk of developing severe immune-related adverse events. In addition to key markers, a higher degree of suspicion and early intervention are needed to improve outcomes in acquired hemophagocytic lymphohistiocytosis, especially with the increasingly and expanding use of immune activation. BioMed Central 2022-10-04 /pmc/articles/PMC9531226/ /pubmed/36195892 http://dx.doi.org/10.1186/s13256-022-03585-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Rubio-Perez, Jaime Rodríguez-Perez, Ángel Ricardo Díaz-Blázquez, María Moreno-García, Victor Dómine-Gómez, Manuel Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature |
title | Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature |
title_full | Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature |
title_fullStr | Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature |
title_full_unstemmed | Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature |
title_short | Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature |
title_sort | treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531226/ https://www.ncbi.nlm.nih.gov/pubmed/36195892 http://dx.doi.org/10.1186/s13256-022-03585-3 |
work_keys_str_mv | AT rubioperezjaime treatmentrelatedhemophagocyticlymphohistiocytosisduetoatezolizumabacasereportandreviewoftheliterature AT rodriguezperezangelricardo treatmentrelatedhemophagocyticlymphohistiocytosisduetoatezolizumabacasereportandreviewoftheliterature AT diazblazquezmaria treatmentrelatedhemophagocyticlymphohistiocytosisduetoatezolizumabacasereportandreviewoftheliterature AT morenogarciavictor treatmentrelatedhemophagocyticlymphohistiocytosisduetoatezolizumabacasereportandreviewoftheliterature AT dominegomezmanuel treatmentrelatedhemophagocyticlymphohistiocytosisduetoatezolizumabacasereportandreviewoftheliterature |